Clinical Trial

A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2025 (before its estimated November 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution twice a day (BID) and four times a day (QID) compared to placebo (vehicle) in the treatment of the signs and symptoms of dry eye. The secondary objective of this study is to evaluate the optimal dosing frequency of 0.25% RCI001 Ophthalmic Solution (BID versus QID) in the treatment of the signs and symptoms of dry eye.
Trial Details
NCT Number NCT07068958
Lead Sponsor ORA, Inc.
Conditions Dry Eye Disease (DED)
Enrollment 200 participants
Start Date 2025-08-01
Primary Completion 2025-11-01 (estimated)
Study Completion 2025-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-16